Recurrent "Boils"? Stop Treating Hidradenitis Suppurativa Like Boils

Are your patients repeatedly presenting with "recurrent boils" in the axillae or groin that just won't resolve with another course of antibiotics or an incision and drainage? It is time to think about Hidradenitis Suppurativa (HS).

In this episode of Synapse, we dive into the management of HS—a chronic, debilitating, and frequently misdiagnosed inflammatory skin disorder affecting roughly 0.67% of the Australian population, primarily women. Join our GP hosts as they unpack why we need to fundamentally shift our approach to this condition. We will explore why HS is a disorder of follicular occlusion and inflammation, not an infection or a result of poor hygiene.

In this episode, we cover:

The Diagnostic Triad: How to confidently diagnose HS clinically by looking for typical lesions (deep-seated nodules, abscesses, and sinus tracts), typical anatomical sites (intertriginous areas like the axillae, groins, and under the breasts), and chronicity.

Common Primary Care Pitfalls: Why treating HS like simple boils adds to scarring, the danger of delaying specialist referrals, and the importance of screening for crucial comorbidities like depression, PCOS, and metabolic syndrome.

Tiered Management Strategies: How to initiate treatment immediately while waiting for a dermatologist. We discuss using topical washes, transitioning to oral antibiotics for their anti-inflammatory (not antibacterial) properties, and utilizing adjuncts like spironolactone or metformin.

The Power of Lifestyle Interventions: Why smoking cessation is the single most impactful lifestyle change you can counsel your patients on to reduce disease severity.

When to Refer: Why you should refer all confirmed or suspected cases to a dermatologist early, treating simultaneously rather than waiting for first-line therapies to fail.

Tune in to learn how to manage the skin, the comorbidities, the pain, and the psychological impact of HS, and transform the quality of life for patients suffering from this vastly misunderstood condition.

⚠️ Disclaimer: The voices in this podcast are AI-generated. This content is produced for educational and learning purposes only and does not constitute medical advice. Clinical decisions should always be made in accordance with current guidelines, individual patient circumstances, and in consultation with appropriate colleagues and specialists.

Transcript

SPEAKER_00 0:00

You know the exact scenario. It's uh it's a busy Friday afternoon, you've got a patient sitting in your consulting room and they just look completely exhausted.

SPEAKER_01 0:08

Oh, absolutely. And they're probably avoiding eye contact, right? Because they are just deeply, deeply embarrassed.

SPEAKER_00 0:13

Yeah, exactly. They're presenting with what looks like, well, yet another recurrent boil, usually in their axilla or, you know, the groin area.

SPEAKER_01 0:21

Aaron Powell And if you open their file, the pattern practically jumps off the screen at you. I mean, it's just this cycle of misery.

SPEAKER_00 0:27

Aaron Powell It really is. You scroll back and you see they've been prescribed, I don't know, multiple short courses of flukluxicylinder ceflexin.

SPEAKER_01 0:35

Aaron Powell Right. And they've been subjected to repeated, incredibly painful IND procedures, you know, incision and drainage. Aaron Powell Yeah.

SPEAKER_00 0:44

We numb the area, we make the cut, we drain the pus, and they walk out with temporary relief. But nothing is actually improving in the long run.

SPEAKER_01 0:52

Aaron Powell No, because they inevitably come back with a new lesion right next to the old one.

SPEAKER_00 0:56

Aaron Powell It feels like a frustrating game of whack-a-mole, honestly. We're draining one, throwing short course antibiotics at it, and thinking we've won.

SPEAKER_01 1:04

But we keep losing because we've been uh fundamentally misidentifying the game we're playing.

SPEAKER_00 1:09

Aaron Powell Which brings us to the core of what we're doing today. In this deep dive into the clinical sources, we're going to completely reframe this.

SPEAKER_01 1:16

Aaron Powell That's the pivotal shift we need to make. That stubborn, fluctuant lesion. It is almost certainly not a primary bacterial infection. Trevor Burrus, Jr.

SPEAKER_00 1:24

Right. What you are actually looking at is a severe, chronic, and historically mismanaged condition called hydratonitis supertiva or HS.

SPEAKER_01 1:32

And our mission today is to equip you to recognize HS instantly, to stop falling into those common clinical traps we've all been taught.

SPEAKER_00 1:40

Yeah, and to initiate coffinate-tiered management right there in your clinic today. Because GPs hold the absolute pivotal role in changing the trajectory for these patients.

SPEAKER_01 1:49

Aaron Powell We really do. I mean, the average time to an accurate diagnosis for HS is often years.

SPEAKER_00 1:54

Years. That's just it's unacceptable.

SPEAKER_01 1:56

It is heavily underdiagnosed. And during those years of, you know, recurrent boils, the patient is suffering massive structural damage to their skin, not to mention a profound psychological toll.

SPEAKER_00 2:07

Aaron Powell So to stop playing whack-a-mole, we really have to rethink the pathophysiology. Right. I'll admit, when I first started seeing these patients early in my career, my immediate reflex was, well, I see pus, I see erythema, it must be staph.

SPEAKER_01 2:22

That's what we're all taught to look for, yeah. Right.

SPEAKER_00 2:24

But if it's not a primary infection, and we know it's definitely not related to poor hygiene, which is, by the way, a devastating stigma these patients carry, what is actually happening on a cellular level.

SPEAKER_01 2:36

Well, HS is at its core a chronic inflammatory disorder of the apocrine gland-bearing skin.

SPEAKER_00 2:43

Aaron Powell Okay, so it's inflammatory, not infective.

SPEAKER_01 2:46

Exactly. The primary inciting event isn't a bacterial invader breaching the skin barrier, it's actually follicular occlusion.

SPEAKER_00 2:53

So the hair follicle gets blocked.

SPEAKER_01 2:54

Right, by hyperkeratosis. And as the apocrine sweat and sebum continue to be produced, the follicular unit just swells, it stretches, and eventually it ruptures beneath the surface of the skin.

SPEAKER_00 3:05

Aaron Powell Oh, wow. And when that follicle ruptures into the dermis, it spills keratin, hair fragments, and commensal bacteria into an area where they absolutely do not belong.

SPEAKER_01 3:14

Exactly. And the body's immune system just absolutely panics.

SPEAKER_00 3:18

I mean, logically it would.

SPEAKER_01 3:20

You get this massive foreign body inflammatory response. There's a huge recruitment of inflammatory mediators, you know, tumor necrosis, factor alpha, various interleukins.

SPEAKER_00 3:30

Which leads to all that leukocytic infiltration and severe edema.

SPEAKER_01 3:33

Yes. That innate and adaptive immune dysregulation is what actually forms those deep-seated, incredibly painful inflammatory nodules and sterile abscesses.

SPEAKER_00 3:43

Sterile abscesses, that's such a key phrase, which perfectly explains why we see this selectively in apocrine-heavy areas and why the demographics skew the way they do.

SPEAKER_01 3:53

Right. The demographics are very telling.

SPEAKER_00 3:55

In Australia, we're looking at roughly 1% of the population, specifically about 0.67%. And it heavily impacts females over males.

SPEAKER_01 4:03

Yeah, at a ratio of about three to one.

SPEAKER_00 4:05

Aaron Powell And the onset is almost always in the second or third decade of life, right around or after puberty.

SPEAKER_01 4:10

Because the hormonal trigger of puberty activates those aprican glands, setting the stage. And you know, we also need to recognize that HS rarely exists in a vacuum.

SPEAKER_00 4:18

Oh, right. It's part of the follicular occlusion tetrad.

SPEAKER_01 4:22

Yes. So if you have a patient who also has a history of severe cystic acne, polynidal sinus disease, or dissecting cellulitis of the scalp, do you think your radar for HS needs to be highly attuned? Exactly. Because they all share that exact same papophysiology of the blocked rupturing follicle.

SPEAKER_00 4:40

But okay, I have to bring up the elephant in the room here. Go for it. If this isn't an infection, why are we historically so tempted to swab these lesions and prescribe five days of antibacterials? I mean, the swabs do sometimes come back with something.

SPEAKER_01 4:54

Oh, the swab is a massive clinical trap. Bacterial colonization in HS is entirely secondary.

SPEAKER_00 5:00

Secondary. Okay.

SPEAKER_01 5:01

When that follicular unit ruptures and creates a cavernous space under the skin, you get bacterial dysbiosis inside the resulting cavity. It just becomes a breeding ground.

SPEAKER_00 5:09

Right. But if you swab an intact HS nodule.

SPEAKER_01 5:12

It's sterile. Completely sterile. And even if you swab a draining tract, the results often just show normal commensal skin flora or, you know, polymicrobial colonizers.

SPEAKER_00 5:20

Aaron Powell Because the massive inflammation brings the pus, not a primary staphylococcal infection.

SPEAKER_01 5:26

That is exactly it.

SPEAKER_00 5:27

That makes total sense. We've been treating the secondary bystander, the commensal bacteria, and completely ignoring the primary inflammatory fire.

SPEAKER_01 5:35

Aaron Powell Which explains why a five-day course of flucloxicillin is like throwing a cup of water on a house fire.

SPEAKER_00 5:41

Yeah, it does absolutely nothing long term.

SPEAKER_01 5:43

We will discuss the correct use of antibiotics in our tiered management section, though, because they are crucial.

SPEAKER_00 5:49

But we use them as immunomodulators, not bactericidal agents.

SPEAKER_01 5:53

Exactly.

SPEAKER_00 5:53

Let's translate this theory into the standard 15-minute consult. If it's an inflammatory condition masquerading as an infection, and we can't rely on a simple swab to give us a binary yes or no answer.

SPEAKER_01 6:06

How do you confidently diagnose it?

SPEAKER_00 6:08

Right. How do we do it?

SPEAKER_01 6:09

The brilliant part for GPs is that you don't need a single lab test. Diagnosis is entirely clinical.

SPEAKER_00 6:14

Really? Just purely clinical.

SPEAKER_01 6:16

Purely clinical. It's based on a strict diagnostic triad.

SPEAKER_00 6:19

Okay, let's unpack the triad. Number one is typical lesions.

SPEAKER_01 6:23

Right. And we are not just talking about a simple ferunkle here.

SPEAKER_00 6:26

We're looking for deep, painful nodules, fluctuant abscesses, and very distinctively, multi-headed commodones.

SPEAKER_01 6:34

Yes, the double-ended blackheads. And as it progresses, we start seeing epithelialized sinus tracts, basically tunnels under the skin, and dense rope-like scarring.

SPEAKER_00 6:44

Got it. Number two is typical sites. It strongly favors the intertrigenous zones.

SPEAKER_01 6:50

The axillae are the most common, but you also have to check the inguinal and groin folds, the perianal and perineal areas.

SPEAKER_00 6:57

The inner thighs, the buttocks, and the infrarory regions under the breasts.

SPEAKER_01 7:02

Right. And the third piece of the triad is chronicity and recurrence.

SPEAKER_00 7:06

So if a patient tells you, I get these all the time, or this boil just won't heal.

SPEAKER_01 7:10

Your HS alarm bell should be deafening.

SPEAKER_00 7:12

But here is a critical GP pitfall regarding the typical sites. You can't just look at the one lesion the patient is willing to show you.

SPEAKER_01 7:18

Oh, absolutely not.

SPEAKER_00 7:19

It's like doing a skin check for suspected melanoma on a patient's forearm, but not asking them to take their shirt off to check their back.

SPEAKER_01 7:26

That is a perfect analogy. You cannot rely on the patient to volunteer the extent of their disease.

SPEAKER_00 7:32

Because these patients are deeply embarrassed. They might present for an axillary lesion, but completely hide the fact that they have painful draining fistulae in their groin.

SPEAKER_01 7:41

Or their gluteal cleft. As the treating GP, you must actively ask for permission and comprehensively examine all apocrine areas.

SPEAKER_00 7:50

You absolutely must, because identifying the true geographic extent and severity of the structural damage is how we stage the disease.

SPEAKER_01 7:59

And accurate staging dictates our management. We use the Hurley staging system for this.

SPEAKER_00 8:04

Let's weave that into a clinical progression. We often see them at Hurley stage first, which is isolated abscess formation.

SPEAKER_01 8:10

Aaron Powell Right. There might be one, there might be multiple, but the defining feature of stage U is that there are no sinus tracts and no scarring yet.

SPEAKER_00 8:17

Aaron Powell So the tissue architecture is still relatively intact.

SPEAKER_01 8:20

Exactly. But if left mismanaged, those recurrent ruptures destroy the dermal architecture. Trevor Burrus, Jr.

SPEAKER_00 8:25

And that brings us to hurly stage two.

SPEAKER_01 8:27

Now you are seeing recurrent abscesses, but they are accompanied by sinus tracts and scarring. However, the lesions are still widely separated by areas of normal skin.

SPEAKER_00 8:37

Okay, so it's spreading that not confluent yet.

SPEAKER_01 8:39

Right. And if the cycle continues unabated, we hit hurly stage third, which is truly devastating.

SPEAKER_00 8:46

This is diffuse or near diffuse involvement across an entire anatomic region, multiple interconnected sinus tracts, massive coalescing plaques of fibrosis.

SPEAKER_01 8:56

And almost constant purulent discharge. It's awful.

SPEAKER_00 8:59

We should briefly mention that the progression isn't identical for everyone, right? You have different phenotypes.

SPEAKER_01 9:05

Yes. The follicular phenotype often starts earlier, features a lot of those multi-headed commodones and nodules, and tends to have a slightly less aggressive structural course.

SPEAKER_00 9:14

Conversely, the inflammatory phenotype is highly aggressive from the jump. It rapidly forms those coalescing fistulae. The pain and the malador are intensely prominent.

SPEAKER_01 9:24

So recognizing the triad and the stages is excellent, but execution in the clinic is where we often stumble.

SPEAKER_00 9:30

Let's talk about those common clinical pitfalls, the bad habits we need to break immediately.

SPEAKER_01 9:34

The first trap is the word we started with. Coding it in your notes as a recurrent boil.

SPEAKER_00 9:39

Because every time you diagnose a boil instead of HS, that patient loses months or years of appropriate systemic treatment.

SPEAKER_01 9:45

Exactly. And that leads directly to the second trap, which I think is the hardest habit for GPs to break the incision and drainage.

SPEAKER_00 9:52

Oh man, I have to put myself in the hot seat here. When a patient presents on a Friday afternoon with an agonizingly tense, fluctuant axillary abscess. It's so tempting. An IND feels like the most compassionate, satisfying thing you can do. You make the incision, the pressure releases, and the patient visibly relaxes. Why are we pushing back against this so hard?

SPEAKER_01 10:14

I completely understand the clinical temptation. You are alleviating acute mechanical pressure, but here is the devastating trade-off. An IND does absolutely nothing to prevent the next lesion from forming, and it practically guarantees dense future fibrosis.

SPEAKER_00 10:29

Oh wow.

SPEAKER_01 10:29

Every time you cut into that inflamed tissue, you are actively contributing to the structural dermal damage and scarring that defines hurley stage two and third.

SPEAKER_00 10:39

So we are making the disease harder to treat in the long run.

SPEAKER_01 10:41

Yes. We really have to put down the scalpel. Intralesional corticosteroids are a much better option for acute flares if you have that capability. But standard IND is a trap.

SPEAKER_00 10:53

Okay, step away from the scalpel. What's the next pitfall?

SPEAKER_01 10:56

Delaying referral. A lot of GPs fall into the habit of sequential treatment.

SPEAKER_00 11:02

Right. We try a topical, wait three months, try an oral, wait three months, then refer.

SPEAKER_01 11:07

Exactly. But with HS, you need to treat A and D refer simultaneously. Do not wait for your primary interventions to fail before getting them in the queue for a dermatologist.

SPEAKER_00 11:17

That's a great point. And we've already covered the pitfall of missing the hidden sites. What about analgesia?

SPEAKER_01 11:23

Undertreating pain is a massive blind spot. Because these look superficially like acute infections, we wrongly assume the pain will simply resolve when the infection clears.

SPEAKER_00 11:31

But it doesn't.

SPEAKER_01 11:32

No, because HS causes chronic, neuropathic, and intense inflammatory pain. The fibrotic scarring literally compresses local nerves.

SPEAKER_00 11:41

Wow. So this condition requires its own dedicated, active pain management plan at every single visit, independent of the disease modifying treatments.

SPEAKER_01 11:51

Absolutely. And the final major pitfall: ignoring smoking status.

SPEAKER_00 11:56

This cannot be overstated. Cigarette smoking is a potent trigger for HS flares.

SPEAKER_01 12:00

Nicotine alters follicular kerotinization and chemotaxes. It literally drives the occlusion that starts the entire cascade.

SPEAKER_00 12:08

And it severely blunts how the patient responds to our treatments, right?

SPEAKER_01 12:11

It does. If you aren't aggressively pushing smoking cessation at every visit, you are fighting a heavily armed enemy with one hand tied behind your back.

SPEAKER_00 12:20

So if we are putting down the scalpel and we aren't writing scripts for five days of cephalexin, what exactly is in our tier GP management toolkit?

SPEAKER_01 12:28

What are we doing to help that patient sitting in our room right now?

SPEAKER_00 12:31

Exactly.

SPEAKER_01 12:31

Let's start with the non-pharmacological baseline, which applies to every patient. Loose clothing to reduce mechanical friction, active smoking cessation, as we just discussed, and weight loss.

SPEAKER_00 12:58

Right. It pumps out pro-inflammatory adipokines like TNF alpha.

SPEAKER_01 13:02

Exactly. Obesity literally sets the systemic immune system to a baseline state of high alert, drastically lowering the threshold for that follicular rupture to spiral out of control.

SPEAKER_00 13:13

Plus, we need active pain management. We aren't just saying take some paracetamol.

SPEAKER_01 13:18

No, we are looking at a ladder involving NSAIDs for the inflammatory component and gavapentinoids or deloxetine for the neuropathic pain caused by the structural scarring.

SPEAKER_00 13:28

And we should refer to a pain specialist if it's highly complex.

SPEAKER_01 13:31

Exactly. Now let's move to the targeted medical therapies. Say you have a patient with mild disease, early stage I.

SPEAKER_00 13:38

For mild disease, we start with topicals. First line is a benzoyl peroxide 5% wash used prophylactically when bathing.

SPEAKER_01 13:45

And if the disease is persistent or recurrent, we add clindamycin 1% lotion applied twice daily.

SPEAKER_00 13:51

But there's a huge caveat here. You only use the clindamycin lotion until the active disease resolves, with a strict maximum limit of three months.

SPEAKER_01 14:00

Because if you use prolonged topical clindamycin monotherapy, you will inevitably breed resistant cutaneous flora, which complicates everything down the line.

SPEAKER_00 14:09

Right. But what if there is no response to topicals or they present with more moderate hurly stage two disease?

SPEAKER_01 14:16

Aaron Powell This is where we bring in the oral antibiotics, but we completely change our mindset.

SPEAKER_00 14:20

Yes. When we use oral antibiotics for HS, we are exploiting their anti-inflammatory and immunomodulatory properties. We are not trying to nuke a staph infection.

SPEAKER_01 14:29

I love the analogy you used earlier using a heavy fire blanket.

SPEAKER_00 14:33

Yeah, you aren't taking a quick five-day sniper shot at a bacterial invader. You are throwing a heavy blanket over the entire immune system for weeks to slowly mesodically smother the inflammatory fire.

SPEAKER_01 14:44

That's exactly how you should frame it to the patient. First line is the tetracycline class. So doxycycline 50 to 100 milligrams daily, or minocycline 50 to 100 milligrams daily.

SPEAKER_00 14:55

And you commit to a full six-week course before you even review for efficacy.

SPEAKER_01 15:00

Yes. And a quick clinical pearl, start at the lower 50 milligram dose in smaller patients to ensure GI tolerability.

SPEAKER_00 15:07

What if tetracyclanes are strictly contraindicated, for instance, in our pregnant patients?

SPEAKER_01 15:12

Then you pivot to the macrolides. Erythromycin base, 250 to 500 milligrams twice daily, or erythromycin ethyl succinate, 400 to 800 milligrams twice daily.

SPEAKER_00 15:24

Again, it's a six-week continuous course to achieve that immunomodulation.

SPEAKER_01 15:28

Exactly. So that's the anti-inflammatory antibiotic base.

SPEAKER_00 15:31

But we all know wait times for a dermatologist can be six months to a year.

SPEAKER_01 15:35

Yeah, it's a real problem.

SPEAKER_00 15:36

There are some incredibly effective systemic adjuncts GPs can initiate while waiting, particularly endocrine modulating treatments.

SPEAKER_01 15:43

Yes, because as we established, hormones drive apocrine gland function. Antiandrogen therapies can be a game changer.

SPEAKER_00 15:49

For female patients, a combined oral contraceptive pill or COCP is a great starting point.

SPEAKER_01 15:55

But you specifically want to prescribe formulations containing antiandrogenic progestogens, things like dianogest, drospirinone, or soproterone.

SPEAKER_00 16:04

Right. You definitely want to avoid highly androgenic progestogens like levinergesterol.

SPEAKER_01 16:08

And if we need heavier antiandrogenic suppression, spironolactone is highly favored here.

SPEAKER_00 16:13

It is fantastic for our female patients. You start low, 25 to 50 milligrams daily, and gradually titrate up to 50 to 100 milligrams as tolerated, reviewing at the six-month mark.

SPEAKER_01 16:24

But as a GP, our immediate reflex has to be safety screening before we even write that script.

SPEAKER_00 16:29

Absolutely. Sparonolactone is strictly contraindicated in pregnancy due to the severe risk of defective viralization of a male fetus.

SPEAKER_01 16:37

You must exclude pregnancy, enforce strict contraception, and counsel them to stop the medication instantly if they plan to conceive.

SPEAKER_00 16:43

Plus, we need baseline and six-monthly monitoring of blood pressure, renal function, and liver function tests.

SPEAKER_01 16:48

Perfect GP oversight. And there is one more vital adjunct, especially for patients with metabolic overlap, metformin modified release.

SPEAKER_00 16:56

Right.

SPEAKER_01 17:01

This is brilliant because it can be used in both male and female patients.

SPEAKER_00 17:04

It directly addresses the insulin dysregulation that so often coexists with HS, especially in PCOS or type 2 diabetes, which feeds right back into that inflammatory cycle.

SPEAKER_01 17:14

Okay, so we've built a robust plan to calm the skin down. But HS doesn't just live in the hair follicle, it is a profoundly systemic issue.

SPEAKER_00 17:24

So true.

SPEAKER_01 17:24

If we are referring them off to a dermatologist for advanced therapies, things like intralesional corticosteroids, systemic retinoids like isotretinin or acetretin, or those TGA-approved biologic injections like a dalamomab for moderate to severe disease, what is the GP's role in the long run?

SPEAKER_00 17:42

The GP has the most important job. The dermatologist manages the skin, you manage the whole patient.

SPEAKER_01 17:47

I love that. Let's talk referral strategy first. The rule is refer all patients early.

SPEAKER_00 17:51

Yes. Treat any refer simultaneously. You must expedite referrals for anyone at early stage two or three therapy.

SPEAKER_01 17:58

If they aren't responding to topical clindamycin, refer. If they have complex fistulae, lymphedema, or severe psychological impact, refer.

SPEAKER_00 18:06

And crucially, if you suspect squamous cell carcinoma or SEC arising in chronic perineal disease, that is an urgent referral.

SPEAKER_01 18:14

Framing this referral is so important for patient trust. If you just hand them a piece of paper and say, I'm sending you to a skin doctor, they feel brushed off.

SPEAKER_00 18:22

Like you're putting them in the too-hard basket.

SPEAKER_01 18:24

Exactly. You need to look them in the eye and say, this is a complex, systemic, inflammatory condition, not a simple infection.

SPEAKER_00 18:32

I am starting you on a comprehensive long-term treatment plan today to calm down your immune system. Simultaneously, I am referring you to a dermatologist who has advanced tools like injectable biologics to manage the structural damage to your skin.

SPEAKER_01 18:47

That immediately validates their suffering and shows you have a master plan.

SPEAKER_00 18:51

And speaking of the whole patient, we have to proactively hunt for the systemic comorbidities.

SPEAKER_01 18:56

You cannot wait for them to bring it up. You must actively screen for obesity, metabolic syndrome, type 2 diabetes, PCOS, inflammatory bowel disease or IBD, and cardiovascular disease or CDD. The chronic systemic inflammation of HS shares deep pathophysiological pathways with all of these.

SPEAKER_00 19:13

And we cannot ignore the psychological devastation. The statistics in the clinical sources are staggering. Clinical depression affects roughly 42% of HS patients.

SPEAKER_01 19:22

The mental health burden is immense. Think about the daily reality: unpredictable, agonizing flares.

SPEAKER_00 19:28

The chronic, malodorous, purulent discharge that ruins clothing and severely impacts social and sexual intimacy.

SPEAKER_01 19:35

It leads to profound isolation. Suicidal ideation is a very real documented risk in this cohort. You must screen for depression and initiate referrals to psychology or psychiatry in parallel with dermatology.

SPEAKER_00 19:48

It really reframes the entire interaction. This isn't just a quick skin console. It's chronic disease management at its highest level.

SPEAKER_01 19:54

Bringing all these threads together for the very next time a patient walks into your clinic complaining of a stubborn boil, what are our core take-home messages?

SPEAKER_00 20:02

Number one, think HS, not boils, anytime you see recurrent painful nodules in intergenenous areas.

SPEAKER_01 20:09

Number two, diagnose confidently and clinically. Look for the triad of typical lesions, typical sites, and chronicity.

SPEAKER_00 20:17

Number three, treat early A and D, refer early. They are never mutually exclusive.

SPEAKER_01 20:22

Number four, push smoking cessation as if their life depends on it, because it is the single most impactful lifestyle change they can make for their disease course.

SPEAKER_00 20:31

And finally, manage the whole patient. The skin, the metabolic comorbidities, the chronic pain, and the psyche.

SPEAKER_01 20:39

It's about taking a step back and seeing the entire physiological picture.

SPEAKER_00 20:42

Aaron Powell Which leads me to a final thought for us to mull over today. We've spent this deep dive dissecting how a supposedly recurrent boil is actually a complex systemic inflammatory disorder driven by genetics, our microbiome, endocrine dipokines, and modern lifestyle factors. Right. It really makes you wonder what other simple localized skin complaints are we currently treating superficially with quick fixes that are actually blaring warning lights on the dashboard for a systemic whole body crisis?

SPEAKER_01 21:10

That is a fascinating question to leave everyone with.

SPEAKER_00 21:12

If this deep dive makes just one GP pause and think of HS the next time they see recurrent axillary abscesses rather than reaching for the scalpel and the flucloxicillin, then we have done our job.

SPEAKER_01 21:24

That is exactly the kind of clinical vigilance that changes lives.

SPEAKER_00 21:27

Thanks for joining us on this deep dive. We'll catch you next time.